CDKN3 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q16667 |
---|---|
Clone Names | 3011501 |
Gene ID | 1033 |
---|---|
Other Names | Cyclin-dependent kinase inhibitor 3, CDK2-associated dual-specificity phosphatase, Cyclin-dependent kinase interactor 1, Cyclin-dependent kinase-interacting protein 2, Kinase-associated phosphatase, CDKN3, CDI1, CIP2, KAP |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7528b was selected from the C-term region of human CDKN3 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CDKN3 (HGNC:1791) |
---|---|
Synonyms | CDI1, CIP2, KAP |
Function | May play a role in cell cycle regulation. Dual specificity CC phosphatase active toward substrates containing either phosphotyrosine or phosphoserine residues (PubMed:8127873, PubMed:8242750). Dephosphorylates CDK2 at 'Thr-160' in a cyclin-dependent manner (PubMed:7569954). |
Cellular Location | Cytoplasm, perinuclear region |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CDKN3 belongs to the dual specificity protein phosphatase family. It was identified as a cyclin-dependent kinase inhibitor, and has been shown to interact with, and dephosphorylate CDK2 kinase, thus prevent the activation of CDK2 kinase. The gene was reported to be deleted, mutated, or overexpressed in several kinds of cancers.
References
Yeh, C.T., et al., Biochem. Biophys. Res. Commun. 305(2):311-314 (2003).Yeh, C.T., et al., Cancer Res. 60(17):4697-4700 (2000).Lee, S.W., et al., Mol. Cell. Biol. 20(5):1723-1732 (2000).Poon, R.Y., et al., Science 270(5233):90-93 (1995).Hannon, G.J., et al., Proc. Natl. Acad. Sci. U.S.A. 91(5):1731-1735 (1994).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.